AZD1775
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cancer
Conditions
Uterine Cancer
Trial Timeline
Oct 22, 2018 → Jul 1, 2027
NCT ID
NCT03668340About AZD1775
AZD1775 is a phase 2 stage product being developed by AstraZeneca for Uterine Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03668340. Target conditions include Uterine Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03668340 | Phase 2 | Active |
| NCT02610075 | Phase 1 | Completed |
Competing Products
20 competing products in Uterine Cancer